Novartis

Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off Novartis shareholders and Novartis ADR…

After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase of international growth, shape…

Ad hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus publishedProposed distribution of a…

Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A receptor antagonist, and…

Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across urticaria disease activity scores1…

Ad hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal to the U.S. Court of Appeals for the…

Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of prioritized therapeutic areas Closing…

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1…

Updated…

Primary…